374 related articles for article (PubMed ID: 35488021)
21. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
22. Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.
Gopcsa L; Réti M; Andrikovics H; Bobek I; Bekő G; Bogyó J; Ceglédi A; Dobos K; Giba-Kiss L; Jankovics I; Kis O; Lakatos B; Mathiász D; Meggyesi N; Miskolczi G; Németh N; Paksi M; Riczu A; Sinkó J; Szabó B; Szilvási A; Szlávik J; Tasnády S; Reményi P; Vályi-Nagy I
Geroscience; 2024 Feb; 46(1):1083-1106. PubMed ID: 37414968
[TBL] [Abstract][Full Text] [Related]
23. Prolonged shedding of viable SARS-CoV-2 in immunocompromised patients with haematological malignancies: A prospective study.
Ichikawa T; Tamura T; Takahata M; Ishio T; Ibata M; Kasahara I; Minauchi K; Yamamoto S; Teshima T; Fukuhara T
Br J Haematol; 2024 Mar; 204(3):815-820. PubMed ID: 37795527
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 infection among patients with haematological disorders: Severity and one-month outcome in 66 Danish patients in a nationwide cohort study.
Glenthøj A; Jakobsen LH; Sengeløv H; Ahmad SA; Qvist K; Rewes A; Poulsen CB; Overgaard UM; Mølle I; Severinsen MT; Strandholdt CN; Maibom J; Kodahl AR; Ryg J; Ravn P; Johansen IS; Helsø SN; Jensen-Fangel S; Kisielewicz J; Wiese L; Helleberg M; Kirk O; Clausen MR; Frederiksen H
Eur J Haematol; 2021 Jan; 106(1):72-81. PubMed ID: 32939853
[TBL] [Abstract][Full Text] [Related]
25. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
Aguareles J; Villares Fernández P; Forné C; Martí-Ballesteros EM; Pradillo Fernández V; Sotres-Fernandez G; de la Fuente-Burguera A; Navarro-San Francisco C; Buzón-Martín LM; García-Delangue T; Aiello FT; Carnevali-Ruiz D; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; García-Casas A; Guisado-Vasco P
Infect Dis (Lond); 2024 Jul; 56(7):575-580. PubMed ID: 38743059
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.
Kakavandi S; Hajikhani B; Azizi P; Aziziyan F; Nabi-Afjadi M; Farani MR; Zalpoor H; Azarian M; Saadi MI; Gharesi-Fard B; Terpos E; Zare I; Motamedifar M
Cell Commun Signal; 2024 Feb; 22(1):126. PubMed ID: 38360719
[TBL] [Abstract][Full Text] [Related]
27. COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit.
Gilioli A; Bresciani P; Franceschini E; Messerotti A; Pioli V; Colasante C; Bettelli F; Giusti D; Forghieri F; Morselli M; Colaci E; Potenza L; Gennari W; Pecorari M; Marasca R; Candoni A; Mussini C; Trenti T; Comoli P; Luppi M; Cuoghi A
Int J Hematol; 2023 Nov; 118(5):652-655. PubMed ID: 37532827
[TBL] [Abstract][Full Text] [Related]
28. Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant.
Lazzari L; Oltolini C; Ciceri F; Giglio F
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34667047
[TBL] [Abstract][Full Text] [Related]
29. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Ljungman P; de la Camara R; Robin C; Crocchiolo R; Einsele H; Hill JA; Hubacek P; Navarro D; Cordonnier C; Ward KN;
Lancet Infect Dis; 2019 Aug; 19(8):e260-e272. PubMed ID: 31153807
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report.
Jarmoliński T; Matkowska-Kocjan A; Rosa M; Olejnik I; Gorczyńska E; Kałwak K; Ussowicz M
Pediatr Transplant; 2021 Aug; 25(5):e13875. PubMed ID: 32949079
[TBL] [Abstract][Full Text] [Related]
31. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.
von Felden J; Alric L; Pischke S; Aitken C; Schlabe S; Spengler U; Giordani MT; Schnitzler P; Bettinger D; Thimme R; Xhaard A; Binder M; Ayuk F; Lohse AW; Cornelissen JJ; de Man RA; Mallet V
J Hepatol; 2019 Sep; 71(3):465-472. PubMed ID: 31108159
[TBL] [Abstract][Full Text] [Related]
32. [SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].
Erensoy S
Mikrobiyol Bul; 2020 Jul; 54(3):497-509. PubMed ID: 32755524
[TBL] [Abstract][Full Text] [Related]
33. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection.
Shah N; Dahi PB; Ponce DM; Sauter CS; Shaffer BC; Chung DJ; Politikos I; Lin RJ; Giralt SA; Papanicolaou G; Ramanathan LV; Perales MA; Kamboj M; Shah GL; Gyurkocza B
Transplant Cell Ther; 2022 Jan; 28(1):55.e1-55.e5. PubMed ID: 34649021
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 in patients with hematologic malignancy.
Langerbeins P; Hallek M
Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
[TBL] [Abstract][Full Text] [Related]
36. Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2.
Wang J; Shao L; Liang J; Wu Q; Zhu B; Deng Q; Liu Z; Liu L; Wang D; Yu Z; Tan X; Wang F; Meng J; Xu X; Xia Z; Li Z; Wang H; Wang L; Wu W; Xie Q; Huang X; Sun Z; Zhang Y; Zhou H; Zhou H; Yang W; Ren H; Liu Z; Qiao M; Tang F; Qi X; Wu H; Deng L; Gao L; Zhang H; Chen P; Zhang H; Zhang X; Zhou J; Chuanqing TU; Guan L; Yin Q; Shu R; Chen F; He M; Wang Q; Guo Z; ;
J Cancer Res Ther; 2023 Dec; 19(6):1495-1500. PubMed ID: 38156914
[TBL] [Abstract][Full Text] [Related]
37. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
39. Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.
Oliva A; Cogliati Dezza F; Petrucci F; Romani FE; Morviducci M; Mirabelli FM; Cancelli F; Valeriani E; Marcelli G; Pugliese F; Turriziani O; Ricci P; Venditti M; Palange P; Mastroianni CM
Clin Exp Med; 2023 Oct; 23(6):2275-2285. PubMed ID: 36867292
[TBL] [Abstract][Full Text] [Related]
40. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
Meir J; Abid MA; Abid MB
Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
